These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22183519)

  • 1. A comparison of the Niagara™ and Dolphin® catheters for continuous renal replacement therapy.
    Kim I; Fealy N; Baldwin I; Bellomo R
    Int J Artif Organs; 2011 Nov; 34(11):1061-6. PubMed ID: 22183519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the Niagara and Medcomp catheters for continuous renal replacement therapy.
    Fealy N; Kim I; Baldwin I; Schneider A; Bellomo R
    Ren Fail; 2013; 35(3):308-13. PubMed ID: 23356529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of saline flush to prevent filter clotting in continuous renal replacement therapy without anticoagulant.
    Panphanpho S; Naowapanich S; Ratanarat R
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S105-10. PubMed ID: 21721435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration.
    Reeves JH; Cumming AR; Gallagher L; O'Brien JL; Santamaria JD
    Crit Care Med; 1999 Oct; 27(10):2224-8. PubMed ID: 10548211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional coagulation and thromboelastograph parameters and longevity of continuous renal replacement circuits.
    Holt AW; Bierer P; Glover P; Plummer JL; Bersten AD
    Intensive Care Med; 2002 Nov; 28(11):1649-55. PubMed ID: 12415456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients.
    Tan HK; Baldwin I; Bellomo R
    Intensive Care Med; 2000 Nov; 26(11):1652-7. PubMed ID: 11193272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faster Blood Flow Rate Does Not Improve Circuit Life in Continuous Renal Replacement Therapy: A Randomized Controlled Trial.
    Fealy N; Aitken L; du Toit E; Lo S; Baldwin I
    Crit Care Med; 2017 Oct; 45(10):e1018-e1025. PubMed ID: 28658026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Access in Patients Treated with Continuous Renal Replacement Therapy: A Report from a Single Center in China.
    Ren H; Ge Y; He X; Li C; Xu B; Gong D; Liu Z
    Ther Apher Dial; 2019 Dec; 23(6):562-569. PubMed ID: 30843338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding].
    Yin Y; Zhao C; Hu Z; Wei S; Huo Y
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 May; 27(5):343-8. PubMed ID: 26003637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure.
    Chua HR; Baldwin I; Bailey M; Subramaniam A; Bellomo R
    J Crit Care; 2012 Dec; 27(6):744.e7-15. PubMed ID: 23102533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variables associated with circuit life span in critically ill patients undergoing continuous renal replacement therapy: a prospective observational study.
    Zhang Z; Ni H; Lu B
    ASAIO J; 2012; 58(1):46-50. PubMed ID: 22210650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.
    Morabito S; Guzzo I; Solazzo A; Muzi L; Luciani R; Pierucci A
    J Nephrol; 2003; 16(4):566-71. PubMed ID: 14696760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.
    Kiser TH; MacLaren R; Fish DN; Hassell KL; Teitelbaum I
    Pharmacotherapy; 2010 Nov; 30(11):1117-26. PubMed ID: 20973685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Argatroban for anticoagulation in continuous renal replacement therapy.
    Link A; Girndt M; Selejan S; Mathes A; Böhm M; Rensing H
    Crit Care Med; 2009 Jan; 37(1):105-10. PubMed ID: 19050602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insertion side, body position and circuit life during continuous renal replacement therapy with femoral vein access.
    Kim IB; Fealy N; Baldwin I; Bellomo R
    Blood Purif; 2011; 31(1-3):42-6. PubMed ID: 21160179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous venovenous hemofiltration without anticoagulation.
    Uchino S; Fealy N; Baldwin I; Morimatsu H; Bellomo R
    ASAIO J; 2004; 50(1):76-80. PubMed ID: 14763495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
    Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
    Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of anticoagulation versus saline flushes in continuous renal replacement therapy.
    Nagarik AP; Soni SS; Adikey GK; Raman A
    Saudi J Kidney Dis Transpl; 2010 May; 21(3):478-83. PubMed ID: 20427872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study.
    Birnbaum J; Spies CD; Klotz E; Hein OV; Morgera S; Schink T; Ziemer S; Grund MS; Saalmann R; Kox WJ; Lehmann C
    Ren Fail; 2007; 29(3):271-7. PubMed ID: 17497439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.